Researchers create new synthetic heparin

Researchers at the University of North Carolina at Chapel Hill have patented a synthetic version of the drug heparin, called Recomparin, that is less complex chemically and should be easier to produce than previous forms.

Led by Jian Liu, Ph.D., scientists in the UNC School of Pharmacy discovered that they could remove a complex element from the heparin molecule without altering the drug’s function. The component, a single sugar called iduronic acid, is difficult to replicate and was long thought to be an important contributor to heparin’s function as an anticoagulant, Liu said.

“We proved we don’t really need that structure for the anticoagulant effect,” Liu said. “By eliminating the iduronic acid unit, we were able to reduce the structural complexity of the heparin molecule by approximately 50 percent.”

Their findings were published in the Sept. 24, 2007, issue of the journal Chemistry & Biology. The study was supported by a grant from the National Institutes of Health.

Heparin is most commonly used to prevent clots from forming and restricting the flow of blood during and after procedures such as kidney dialysis, heart-bypass surgery, stent implantation and knee and hip replacement. The annual worldwide sales of heparin are estimated at $3 billion.

Heparin is a natural substance that is extracted from animal tissue, chiefly from cows and pigs. Outbreaks of diseases among livestock can interfere with production of the drug, driving up prices and tightening supplies.

“Synthesizing heparin, rather than extracting it from animals, gives us more control over its anticoagulant properties and creates a purer, safer, more reliable drug,” Liu said.

Currently, synthetic forms of heparin are difficult to produce in large quantities because of the drug’s complexity, resulting in expensive therapies that are not widely used, Liu said.

The simpler structure of Recomparin is likely to be easier to produce than other forms of synthetic heparin, Liu says. It is also expected to reduce dangerous side effects, such as uncontrolled bleeding, while providing the same benefits as naturally derived heparin.

The next step for Recomparin will be to find a company to license the drug and begin the process of getting Food and Drug Administration approval.

Source: University of North Carolina at Chapel Hill

Related stories:

Hospital error blamed for more infant overdoses
(AP) -- The case of 14 babies who received accidental overdoses while in intensive care has raised new questions about how a common blood-thinning medication could be given to infants repeatedly in the wrong dosage.
Hospital says its pharmacy error led to infant ODs
(AP) -- A hospital in Corpus Christi said Thursday that a mixing error that led to a blood thinner overdose in as many as 17 infants was caused by its pharmacy. Two of the babies involved have died.
US Pharmacopeia announces revised heparin monographs and reference standards
Standards updated in response to public health threat associated with blood-thinning drug's adulteration with over-sulfated chondroitin
The U.S. Pharmacopeial (USP) Convention announces that revised monographs for heparin sodium and heparin calcium in the United States Pharmacopeia (USP) are now available and official on the USP Web site. The revised monographs are accompanied by two new and two updated official USP Reference Standards. These public standards allow any party—and particularly the Food and Drug Administration (FDA) and manufacturers—to test heparin sodium and calcium drug substances to assure their quality. All drug manufacturers who market heparin in the United States are required to meet these newly revised standards. The heparin monographs were updated in the interest of public health following the deaths of more than 200 people earlier this year. These deaths are suspected to have resulted from the adulteration of the blood thinner with over-sulfated chondroitin, which is derived from the chemical chondroitin and used in dietary supplements.
Fewer than 1 in 5 patients receive treatment to prevent life-threatening blood clots
Fewer than 1 in 5 patients received post-discharge therapy to prevent life-threatening blood clots — venous thrombosis — after hip- or knee-replacement surgery, report Rahme and colleagues in a retrospective cohort study. Venous thrombosis is one of the leading causes of death among hospital patients. However, elderly patients have a 70% lower chance of dying within 3 months if they take an anticoagulant drug to prevent blood clots.
Findings released from 1 of the largest percutaneous coronary intervention trials ever
A study led by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center/NewYork-Presbyterian and chairman of the Cardiovascular Research Foundation, has shown that heart attack patients who were administered the direct thrombin inhibitor bivalirudin during primary angioplasty had a reduced rate of adverse clinical events, a lower rate of major bleeding, and a lower mortality rate than those who were treated with a regimen of heparin and glycoprotein IIb/IIIa inhibitors (GPI).
Landmark study reveals superiority of bivalirudin in heart attack patients at 30 days
The Cardiovascular Research Foundation (CRF) announced today that the New England Journal of Medicine published results of the HORIZONS AMI trial which showed the use of the anticoagulant bivalirudin following angioplasty in heart attack patients reduced net adverse clinical events by 24 percent compared to the standard treatment, as well as reduced the risk of overall mortality by 33 percent and cardiac mortality by 38 percent.
Undergrad has sweet success with invention of artificial Golgi
An undergraduate student at Rensselaer Polytechnic Institute has learned very quickly that a spoonful of sugar really does help the medicine go down. In fact, with his invention, the sugar may actually be the medicine.
Baxter may stay out of Heparin business
The head of Baxter International Inc. said the company has not decided whether it will resume selling the blood thinner heparin in the United States.

News discussion:

Medicine & Health news